The Financial Post reports in its Thursday edition that as cannabis legalization spreads across the globe, another mind- altering drug is trying to follow in its tracks: magic mushrooms. A Bloomberg dispatch to the Post says that Denver voted in May to decriminalize the fungus that contains psilocybin, a psychedelic compound. Oakland, Calif., followed Denver's lead a few weeks later and Oregon is trying to get a similar measure on the ballot for 2020. Advocates say mushrooms have untapped medical potential that could be as big as cannabis, particularly for treating depression and addiction. The Food and Drug Administration granted "breakthrough therapy" status in October to Compass Pathways to test the drug for treatment-resistant depression, expediting the development process. The London-based company says it is now proceeding with a large-scale clinical trial in Europe and North America. "The medical and therapeutic applications are becoming incontrovertible in a world where depression is one of the most commonly diagnosed conditions," said Ronan Levy, a former executive at Aurora Cannabis and co-founder of Toronto-based Field Trip Ventures, a start-up focused on therapeutic psychedelics including mushrooms.